Dr. Shedlock has served as vice president, preclinical development at Poseida Therapeutics since October 2017. Dr. Shedlock has extensive experience in the field of T-cell immunology and was formerly an adjunct assistant professor of pathology & laboratory medicine at the Perelman School of Medicine, as well as associate director of the T-Cell Engineering Laboratory that is part of Carl June’s group at the University of Pennsylvania. Prior to his work developing engineered T lymphocyte-based therapies for treating cancer, he led a team in the development of DNA vaccines against numerous pathogens from the preclinic to clinical trials, including those targeting the human herpes viruses and a vaccine for Ebola. He also established numerous animal models for evaluation of vaccine immunogenicity and efficacy, molecular adjuvants, genetic optimization strategies and advanced delivery technologies. Previously, he studied the mechanisms of antibody-mediated neutralization of Ebola as a postdoctoral fellow at the Vaccine Research Center, National Institutes of Health. Dr. Shedlock received his Ph.D. from the University of Pennsylvania, investigating the role of helper T cells in the generation of immunity, and was awarded the Saul Winegrad Award for an exceptional dissertation and significant contribution to biomedical science.